Description
The ProbeSeq Cancer Antigen 125 (CA125 / MUC16) Nanobody is a recombinant single-domain antibody (VHH) engineered for high-affinity and selective binding to human CA125, a large transmembrane mucin glycoprotein widely used as a tumor-associated biomarker. This nanobody supports research-use diagnostic assay development, oncology biomarker detection, and advanced biosensor integration.
CA125 is a clinically validated biomarker extensively used in ovarian cancer detection, disease progression monitoring, and therapeutic response assessment. Elevated circulating CA125 levels are associated with tumor burden and cancer progression, making sensitive detection critical for oncology research, liquid biopsy studies, and rapid diagnostic technology development.
Derived from camelid heavy-chain antibody architecture, this nanobody consists of a single monomeric VHH domain (~15 kDa) providing strong antigen recognition, rapid binding kinetics, and high structural stability. Compared with conventional antibodies, nanobodies offer superior thermal stability, reduced steric hindrance, and efficient surface immobilization, enabling high-performance detection in electrochemical biosensors, microfluidic platforms, and miniaturized diagnostic systems.
Typical assay workflows use sample input volumes ranging from approximately 5–50 µL depending on platform configuration and detection method. The nanobody is compatible with serum, plasma, cell lysates, extracellular vesicles, and buffered biological samples following appropriate assay optimization.
What’s Included
Recombinant anti-CA125 single-domain VHH nanobody
Sequence and expression documentation for research traceability
Reconstitution and handling guidelines
Custom affinity tags (His-tag, biotin, Fc fusion), labeling options, and bulk production available upon request
Target Strategy
Engineered for high binding specificity to CA125 extracellular epitopes
Minimal cross-reactivity with unrelated mucin proteins
Stable binding under physiological conditions
Compatible with biosensor surface functionalization and immunoassay workflows
Product Format
Lyophilized format
Delivered dry for enhanced stability
Reconstitute in PBS or preferred buffer
Solution format
Supplied in PBS-based storage buffer
Typical concentration range 0.5–1 mg/mL
Tagged variants available upon request
Performance Orientation
Electrochemical biosensors
Oncology biomarker detection assays
Microfluidic and lab-on-chip systems
Surface immobilization workflows
Optical and fluorescence detection platforms
Point-of-care cancer diagnostic research devices
Quality Control
Sequence confirmation
Purity validation (SDS-PAGE / chromatography)
Binding verification testing
Concentration determination
Manufacturing quality review
Certificate of Analysis (CoA) available upon request
Applications
Ovarian cancer biomarker detection research
Tumor progression monitoring studies
Liquid biopsy and cancer profiling research
Immunoassay and biosensor development
Microfluidic diagnostic platform integration
Point-of-care oncology monitoring research
Storage
Store at –20 °C for long-term storage or 4 °C for short-term use.
Lyophilized nanobody stable for up to 12 months under recommended conditions. Avoid repeated freeze–thaw cycles.
